Slide 1: Investor Presentation
Investor Presentation Chloe The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements
Slide 3: Insulet at a Glance
1 Insulet at a Glance Dan Podder since 2019 3
Slide 4: Our mission is to improve the lives of people with diabetes
Our mission is to improve the lives of people with diabetes and enable our customers to enjoy simplicity, freedom, and healthier lives through innovative technology. 4
Slide 5: Timing is Everything – And Ours is Now
Timing is Everything – And Ours is Now “ For 30+ years it was vials and injections, and I got used to it. I was the old dog that didn’t want to learn a new trick. And then my son’s friend, who at the time was 5 years old, he is wearing the Omnipod and he goes, ‘I’m wearing one. How come you’re not w
Slide 6: The Global Leader in Diabetes Management
The Global Leader in Diabetes Management The first AID system #1 U.S. requested and prescribed AID system1,2 FDA-cleared for both #1 U.S. new customer starts since 20233 type 1 and type 2 in the U.S. #1 AID amongst new users in EU4 $2.1B 500K 365K 25 2024 Revenue Active Customers5 Using Omnipod 55 G
Slide 7: Track Record of Delivering Results
Track Record of Delivering Results Growing Revenue Leading Rapidly Expanding Beyond $2.5B Gross Margin Adjusted Operating Margin ~24% ~660 bps ~1,000 bps CAGR Expansion Expansion 17%-17.5% 1 1 2 1 1. Reflects midpoint of full year 2025 revenue guidance range of 24%-27% constant currency growth, and
Slide 8: Omnipod 5 Addresses the Unmet Needs of People Living with Type 1 and Type 2 Diabetes
Omnipod 5 Addresses the Unmet Needs of People Living with Type 1 and Type 21 Diabetes First and only tubeless, waterproof2 AID in the U.S. World-class algorithm built into the Pod Choice of sensor integration3 Phone control4 with Android or iOS Significant improvements in glycemic results & quality
Slide 9: Driving Adoption as First Mover in Type 2
Driving Adoption as First Mover in Type 2 Strong SECURE-T2D clinical results: U.S. FDA clearance for adults with Type 2 diabetes received August 2024 Baseline 8.2 • Expand relationships and deepen call points with Endos -0.8% 1 and high-prescribing PCPs 13 Weeks 7.4 • Lead with evidence – data demon
Slide 10: Scale and Differentiated Platform Supports Durable, Profitable Growth
Scale and Differentiated Platform Supports Durable, Profitable Growth Unique Widespread, Pioneer in Rich Data Form Factor Affordable Advanced Ecosystem Access Automation Tubeless, discreet, Available in more than $1B+ investment over Cloud connectivity wearable AID protected 47,000 U.S. pharmacies l
Slide 11: Executing on a Large Market Opportunity
Executing on a Large 2 Market Opportunity David Podder since 2020 11
Slide 12: Durable Growth Company in a Large, Underpenetrated Market
Durable Growth Company in a Large, Underpenetrated Market ~3.5M 3.0M+ ~3.5M ~14M ~2.5M Total Addressable ~1.7M Market1 of Patients We are well-positioned to improve the lives of ~40% ~20% millions of people with ~5% diabetes globally U.S. T1D Int'l T1D U.S. T2D U.S. T2D Int'l T2D Basal-Bolus Basal-O
Slide 13: Omnipod 5: Accelerating the Pace of Innovation
Omnipod 5: Accelerating the Pace of Innovation Product Vision At launch Today (FMR August 2022) Omnipod of the Future Tubeless wearable disposable form factor Continuous focus on product enhancement Sensor integration G6 G6 G7 FSL2+ Markets U.S. U.S. & International Seamless integration with custome
Slide 14: Expanding Lead in Type 1 and Creating the Market in Type 2
Expanding Lead in Type 1 and Creating the Market in Type 2 ~29% • Drive adoption through market CAGR development and awareness of strong clinical data • Build customer base to further strengthen recurring revenue model • Invest in commercial excellence and a 1 modernized end-to-end customer experien
Slide 15: Strengthening Market Presence Outside the U.S.
Strengthening Market Presence Outside the U.S. • Invest in market development capabilities ~18% • Utilize clinical evidence to expand prescribers and access CAGR • Accelerate pace of Omnipod 5 adoption 2023 2024 2025 Launched January UK France Italy Norway Finland Sweden Denmark March April Germany
Slide 16: Building the Power of our Omnipod 5 Brand Globally
Building the Power of our Omnipod 5 Brand Globally 2022 2023 2024 2025 FMR Germany UK Netherlands Italy The Nordics* Australia Belgium Omnipod 5 (August) (June) (June) (January) (January) (March) (March) (August) UK France U.S. T2D Canada Switzerland (June) (June) (August) (April) (April) *Nordics r
Slide 17: Innovating to Improve Lives and Preserve Our Planet
Innovating to Improve Lives and Preserve Our Planet Sustainability Strategic Pillars1 Recognition2 ESG Ratings Sustainable People and Resilient Operations Product Innovation Communities ESG Rankings 7.4M Pods Insulet for 11% Of our annual global electricity needs met with renewable energy Accepted t
Slide 18: Well-Positioned for Durable, Profitable Growth
Unique Omnipod 5 platform; first AID cleared for T2D Strong clinical outcomes and customer experience Well- transform Podders lives Positioned for $1B invested in advanced automation and global Durable, supply chain enables sustainable cost advantage Profitable U.S. pharmacy pay-as-you-go model make
Slide 19: Driven by Our Commitment to Improve the Lives of People with Diabetes
Driven by Our Commitment to Improve the Lives of People with Diabetes “ Omnipod 5 has been life changing for me. Now I know my glucose levels, and Omnipod 5 does all the insulin calculations for me. My glucose is steady with fewer “ highs and lows and the terrible symptoms associated with that. It’s
Slide 20: Thank You
Thank You
Slide 21: Appendix
Appendix Insulet
Slide 22: Insulet Common Abbreviations and Acronyms
Insulet Common Abbreviations and Acronyms A1c Blood test measures average blood glucose levels over the last 3 months iOS iPhone Operating System AID Automated Insulin Delivery LEED Leadership in Energy and Environmental Design bps Basis Points MDI Multiple Daily Injections CAGR Compounded Annual Gr
Slide 23: Q2 2025 Performance
Q2 2025 Performance Total Revenue Omnipod Revenue by Geography Other Financial Highlights U.S. Omnipod $453.2M GR OS S M AR GIN 28.7% 69.7% Total Company Total Omnipod $649.1M $639.0M up 190 bps 32.9%, 33.0%, A D JU S T E D 31.3% constant currency1 31.4% constant currency1 O P ER AT IN G M A RG IN 1
Slide 24: Q2 2025 Commercial Metrics
Q2 2025 Commercial Metrics Delivered NCS Growth: • YoY & QoQ • in U.S. & International • in T1D & T2D OVER OVER OVER OVER 85% 30% 90% 50% U.S. NCS U.S. NCS U.S. International MDI T2D Customer Base with Customer Base with Omnipod 5 Omnipod 5 24 Note: Commercial metrics are directional estimates deriv
Slide 25: Q2 2025 Revenue & Margin Performance
Q2 2025 Revenue & Margin Performance1,2 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin U.S. Omnipod International Omnipod Adjusted Operating Income & Margin 2 1. Growth rates are on a YoY basis and are in constant currency; constant currency amounts are non-GAAP financial measures.
Slide 26: 2025 YTD Revenue & Margin Performance
2025 YTD Revenue & Margin Performance1,2 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin U.S. Omnipod International Omnipod Adjusted Operating Income & Margin 2 1. Growth rates are on a YoY basis and are in constant currency; constant currency amounts are non-GAAP financial measures
Slide 27: Historical Financial Performance
Historical Financial Performance $s in Millions Total Revenue1 Total Omnipod1 Gross Profit & Margin (adjusted) 2 2 U.S. Omnipod1 International Omnipod1 Operating Income & Margin (adjusted) 2 2 1. Growth rates are on a YoY basis and are in constant currency; constant currency amounts are non-GAAP fin
Slide 28: FY 2025 Guidance
FY 2025 Guidance1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q3 2025 FY 2025 FY 2025 FY 2025 Continued strong Omnipod 5 Revenue Revenue Gross Margin Adjusted Operating adoption globally Raise Margin3 Raise U.S. & International annual NCS growth YoY 22% - 25% 24% - 27% ~71% 17% - 17.5% M
Slide 29: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 22% to 25% —% 22% to 25% International Omnipod 37% to 40% 3% 34% to 37% Total Omnipod 26% to 29% 1% 25% to 28% Drug Delivery (30)% to (25)% —% (30)% to (25)% To
Slide 30: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures Q2'2025 Q2'2024 YTD 2025 YTD 2024 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Revenue GAAP Growth Rate 32.9 % 23.2% 30.9 % 23.3 % 22.1 % 30.0% 18.8 % 21.5 % 22.5 % Less: Currency Impact 1.6% (0.2)% 0.4% 0.2% 0.2% 0.4% (3.7)% 1.8% 0.6% Constant Currenc